CENTER
VALLEY, Pa., May 16, 2024
/PRNewswire/ -- Olympus, a global medical technology company
committed to making people's lives healthier, safer and more
fulfilling, announced today that it will highlight its EVIS X1™
endoscopy system and colorectal cancer screening solutions during
the Digestive Disease Week annual meeting May 19-21 in Washington, D.C.
The American Cancer Society reports that colorectal cancer
deaths have been dropping in older adults for decades likely, in
part, due to screenings such as colonoscopy that find polyps before
they can develop into cancer or finding cancer earlier when it's
more treatable.1
The EVIS X1 endoscopy system features imaging technologies
designed to help physicians diagnose, treat and observe diseases
and disorders of the upper and lower GI tract, including colorectal
cancer.
More than 20 years ago, colorectal cancer (CRC) was known to be
the fourth-leading cause of cancer death in men and women under the
age of 50, according to the American Cancer Society. Now, CRC is
the leading cause of cancer death for men under the age of 50 and
the second leading cause for women under 50. Since 2015, incidence
rates of CRC in adults younger than 55 have increased by 1% to 2%
annually.2
The EVIS X1 endoscopy system imaging technologies include
Texture and Color Enhancement Imaging (TXI™) technology, which can
improve the visibility of potential lesions and may help physicians
reduce miss rates for early mucosal changes that can lead to
cancer.3
A study evaluating the use of TXI technology on polyp detection
during screening colonoscopies found that TXI technology
significantly increased physicians' adenoma detection rate (ADR)
and increased the number of adenomas measuring 5mm or larger
detected, as compared to those found during a procedure using
high-definition white-light endoscopy. ADR was also higher with TXI
technology (as compared to white light) in patients who were being
screened as a result of a positive non-invasive test or due to a
history of polyps or bowel cancer.4
TXI technology is not intended to replace histopathological
sampling as a means of diagnosis.
Other assistive technologies that may increase ADR and help
advance colorectal cancer detection include mechanical devices such
as the Olympus® Endocuff Vision™ device, which help
increase ADR during a colonoscopy by manipulating colonic folds and
maximizing the viewable mucosa.5
A rare but potential complication when using Endocuff Vision™
device is the detachment of the device during the procedure. The
physician should be prepared to retrieve the device if this were to
occur. The physician should ensure Endocuff Vision™ device is
used only with compatible colonoscopes, that the colonoscope distal
tip is in good condition, and that the device is fully seated on
the distal tip prior to the application of lubricant to minimize
the chance of detachment. Standard risks of colonoscopy including
injury, bleeding and perforation still apply when using the
Endocuff Vision™ device.
During DDW, Olympus will demonstrate the capabilities of the
EVIS X1 system and Endocuff Vision device, as well as offer
hands-on demonstrations of ERCP and ESD procedures, live
demonstrations of EUS-guided liver biopsy and presentations about
the EndoClot® Polysaccharide Hemostatic System (PHS) and
Submucosal Injection Solution (SIS) and automation in endoscope
reprocessing.
For more information, visit the Olympus booth, #3329, during DDW
or visit the EVIS X1 endoscopy system product page or the
gastroenterology page for the entire Olympus® GI
portfolio.
About Olympus
At Olympus, we are committed to our purpose of making people's
lives healthier, safer and more fulfilling. As a global medical
technology company, we partner with healthcare professionals to
provide solutions and services that will help them with early
detection, diagnosis and minimally invasive treatment, aiming to
improve patient outcomes by elevating the standard of care in
targeted disease states.
For more than 100 years, Olympus has pursued a goal of
contributing to society by producing products designed with the
purpose of delivering optimal outcomes for its customers around the
world.
Olympus Corporation of the Americas, a wholly owned subsidiary
of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs
more than 4,500 employees throughout locations in North and
South America. For more
information, visit olympusamerica.com.
1 American Cancer Society, "Key Statistics for
Colorectal Cancer." Rev. Jan. 17,
2024
2 "Cancer statistics, 2024," CA: A Cancer Journal for
Clinicians." Pub. Jan. 17, 2024
3 Data on file with Olympus (DC00489968)
4 Young, E; et al, "Texture and Color Enhancement
Imaging Improves Colonic Adenoma Detection: A Multicenter
Randomized Controlled Trial." Gastroenterology AGA Journal, pub.
October 2023
5 Data on file with Olympus as of 12/2016
View original content to download
multimedia:https://www.prnewswire.com/news-releases/olympus-to-highlight-evis-x1-endoscopy-system-and-colorectal-cancer-screening-solutions-at-digestive-disease-week-annual-meeting-302148185.html
SOURCE Olympus Corporation of the Americas